Muscular dystrophies (MDs) are a group of genetic diseases characterized by progressive muscle wasting associated to oxidative stress and persistent inflammation. It is essential to deepen our knowledge on the mechanism connecting these two processes because current treatments for MDs have limited efficacy and/or are associated with side effects. Here, we identified the alarmin high-mobility group box 1 (HMGB1) as a functional link between oxidative stress and inflammation in MDs. The oxidation of HMGB1 cysteines switches its extracellular activities from the orchestration of tissue regeneration to the exacerbation of inflammation. Extracellular HMGB1 is present at high amount and undergoes oxidation in patients with MDs and in mouse models of Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophy 3 (LGMDR3) compared to controls. Genetic ablation of HMGB1 in muscles of DMD mice leads to an amelioration of the dystrophic phenotype as evidenced by the reduced inflammation and muscle degeneration, indicating that HMGB1 oxidation is a detrimental process in MDs. Pharmacological treatment with an engineered nonoxidizable variant of HMGB1, called 3S, improves functional performance, muscle regeneration, and satellite cell engraftment in dystrophic mice while reducing inflammation and fibrosis. Overall, our data demonstrate that the balance between HMGB1 redox isoforms dictates whether skeletal muscle is in an inflamed or regenerating state, and that the nonoxidizable form of HMGB1 is a possible therapeutic approach to counteract the progression of the dystrophic phenotype. Rebalancing the HMGB1 redox isoforms may also be a therapeutic strategy for other disorders characterized by chronic oxidative stress and inflammation.

Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophy / G. Careccia, M. Saclier, M. Tirone, E. Ruggieri, E. Principi, L. Raffaghello, S. Torchio, D. Recchia, M. Canepari, A. Gorzanelli, M. Ferrara, P. Castellani, A. Rubartelli, P. Rovere-Querini, M. Casalgrandi, A. Preti, I. Lorenzetti, C. Bruno, R. Bottinelli, S. Brunelli, S.C. Previtali, M.E. Bianchi, G. Messina, E. Venereau. - In: SCIENCE TRANSLATIONAL MEDICINE. - ISSN 1946-6234. - 13:596(2021 Jun 02), pp. eaay8416.1-eaay8416.13. [10.1126/scitranslmed.aay8416]

Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophy

G. Careccia;M. Saclier
Methodology
;
M.E. Bianchi;G. Messina;
2021

Abstract

Muscular dystrophies (MDs) are a group of genetic diseases characterized by progressive muscle wasting associated to oxidative stress and persistent inflammation. It is essential to deepen our knowledge on the mechanism connecting these two processes because current treatments for MDs have limited efficacy and/or are associated with side effects. Here, we identified the alarmin high-mobility group box 1 (HMGB1) as a functional link between oxidative stress and inflammation in MDs. The oxidation of HMGB1 cysteines switches its extracellular activities from the orchestration of tissue regeneration to the exacerbation of inflammation. Extracellular HMGB1 is present at high amount and undergoes oxidation in patients with MDs and in mouse models of Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophy 3 (LGMDR3) compared to controls. Genetic ablation of HMGB1 in muscles of DMD mice leads to an amelioration of the dystrophic phenotype as evidenced by the reduced inflammation and muscle degeneration, indicating that HMGB1 oxidation is a detrimental process in MDs. Pharmacological treatment with an engineered nonoxidizable variant of HMGB1, called 3S, improves functional performance, muscle regeneration, and satellite cell engraftment in dystrophic mice while reducing inflammation and fibrosis. Overall, our data demonstrate that the balance between HMGB1 redox isoforms dictates whether skeletal muscle is in an inflamed or regenerating state, and that the nonoxidizable form of HMGB1 is a possible therapeutic approach to counteract the progression of the dystrophic phenotype. Rebalancing the HMGB1 redox isoforms may also be a therapeutic strategy for other disorders characterized by chronic oxidative stress and inflammation.
Animals; Humans; Mice; Mice, Inbred mdx; Muscle, Skeletal; Oxidation-Reduction; Protein Isoforms; HMGB1 Protein; Muscular Dystrophy, Duchenne
Settore BIO/17 - Istologia
2-giu-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Careccia STM 2021.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 8.29 MB
Formato Adobe PDF
8.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/859298
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 23
social impact